These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21864232)

  • 1. Potential anticancer properties of bisphosphonates: insights from preclinical studies.
    Clezardin P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):102-13. PubMed ID: 21864232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential anticancer properties of bisphosphonates.
    Neville-Webbe HL; Gnant M; Coleman RE
    Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
    Aft R
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?
    Hirsh V
    Anticancer Agents Med Chem; 2012 Feb; 12(2):137-43. PubMed ID: 21864233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
    Gnant M; Clézardin P
    Cancer Treat Rev; 2012 Aug; 38(5):407-15. PubMed ID: 21983264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate anticancer activity in multiple myeloma.
    Terpos E
    Anticancer Agents Med Chem; 2012 Feb; 12(2):123-8. PubMed ID: 21864228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence.
    Santini D; Stumbo L; Spoto C; D'Onofrio L; Pantano F; Iuliani M; Fioramonti M; Zoccoli A; Ribelli G; Virzì V; Vincenzi B; Tonini G
    Breast Cancer Res; 2015 Sep; 17(1):121. PubMed ID: 26328589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapies of bone disease with bisphosphonates.
    Syddall SP; Ottewell PD; Holen I
    Curr Pharm Des; 2010; 16(27):2988-97. PubMed ID: 20722617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
    Saad F; Mulders P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
    Li J; Rugo HS
    Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of bisphosphonates in cancer therapy.
    Lüftner D; Henschke P; Possinger K
    Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer activity of bisphosphonates in breast cancer.
    Gnant M
    Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates and breast cancer prevention.
    Chlebowski RT; Col N
    Anticancer Agents Med Chem; 2012 Feb; 12(2):144-50. PubMed ID: 21864227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of bisphosphonates: promising preclinical evidence.
    Guise TA
    Cancer Treat Rev; 2008; 34 Suppl 1():S19-24. PubMed ID: 18486348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bone-targeted agents on cancer progression and mortality.
    Coleman R; Gnant M; Morgan G; Clezardin P
    J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates as treatment of bone metastases.
    Holen I; Coleman RE
    Curr Pharm Des; 2010; 16(11):1262-71. PubMed ID: 20166976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates for breast cancer: questions answered, questions remaining.
    Layman R; Olson K; Van Poznak C
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
    Saad F; Colombel M
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates for advanced prostate cancer.
    Yuen KK; Shelley M; Sze WM; Wilt T; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006250. PubMed ID: 17054286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.